Shattuck Labs, Inc. (STTK)
$7.03-$0.62 (-8.11%) Today
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 5 | 2,562,500 | $250K |
| Open-market sale | 4 | 53,875 | $379K |
| Grant or award | 6 | 486,000 | |
| Option exercise | 8 | 72,056 | |
| Other acquisition / disposition | 8 | 73,759,152 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
53 Form 4 filings on record, the earliest from Oct 8, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Andrew R. Neill - Officer | Tax withholding / forfeiture | Common Stock | 6,660 | $4.75 | $32K | |
| Andrew R. Neill - Officer | Grant or award | Stock Option (Right to Buy) | 549,800 | $0.00 | - | |
| Taylor Schreiber - Officer | Grant or award | Stock Option (Right to Buy) | 1,548,300 | $0.00 | - | |
| ORBIMED ADVISORS LLC - Director | Open-market purchase | Common Stock | 5,255,106 | $0.87 | $4.56M | |
| ORBIMED ADVISORS LLC - Director | Open-market purchase | Common Stock | 1,051,021 | $0.87 | $912K | |
| ORBIMED ADVISORS LLC - Director | Open-market purchase | Pre-Funded Warrants (right to buy) | 10,111,384 | - | - | |
| ORBIMED ADVISORS LLC - Director | Open-market purchase | Pre-Funded Warrants (right to buy) | 2,022,277 | - | - | |
| ORBIMED ADVISORS LLC - Director | Open-market purchase | Common Warrants (right to buy) | 15,366,490 | - | - | |
| ORBIMED ADVISORS LLC - Director | Open-market purchase | Common Warrants (right to buy) | 3,073,298 | - | - | |
| Mona Ashiya - Director | Open-market purchase | Common Stock | 5,255,106 | $0.87 | $4.56M | |
| Mona Ashiya - Director | Open-market purchase | Common Stock | 1,051,021 | $0.87 | $912K | |
| Mona Ashiya - Director | Open-market purchase | Pre-Funded Warrants (right to buy) | 10,111,384 | - | - | |
| Mona Ashiya - Director | Open-market purchase | Pre-Funded Warrants (right to buy) | 2,022,277 | - | - | |
| Mona Ashiya - Director | Open-market purchase | Common Warrants (right to buy) | 15,366,490 | - | - | |
| Mona Ashiya - Director | Open-market purchase | Common Warrants (right to buy) | 3,073,298 | - | - | |
| Mona Ashiya | Grant or award | Stock Option (Right to Buy) | 66,300 | $0.00 | - | |
| Daniel G. Baker | Grant or award | Stock Option (Right to Buy) | 66,300 | $0.00 | - | |
| Andrew R. Neill - Officer | Grant or award | Common Stock | 64,027 | $0.87 | $56K | |
| Andrew R. Neill - Officer | Grant or award | Warrants (Right to Buy) | 64,027 | - | - | |
| Stephen Stout - Officer | Grant or award | Common Stock | 12,805 | $0.87 | $11K | |
| Stephen Stout - Officer | Grant or award | Warrants (Right to Buy) | 12,805 | - | - | |
| Taylor Schreiber - Officer | Grant or award | Common Stock | 25,610 | $0.87 | $22K | |
| Taylor Schreiber - Officer | Grant or award | Warrants (Right to Buy) | 25,610 | - | - | |
| Abhinav A. Shukla - Officer | Grant or award | Common Stock | 5,122 | $0.87 | $4K | |
| Abhinav A. Shukla - Officer | Grant or award | Warrants (Right to Buy) | 5,122 | - | - | |
| Redmile Group, LLC - Director | Grant or award | Pre-Funded Warrants to Purchase Common Stock | 4,097,730 | - | - | |
| Redmile Group, LLC - Director | Grant or award | Common Warrants to Purchase Common Stock | 4,097,730 | - | - | |
 Clay B. Siegall | Grant or award | Common Stock | 128,054 | $0.87 | $111K | |
| Clay B. Siegall | Grant or award | Warrants (Right to Buy) | 128,054 | - | - | |
| Tyler Brous | Grant or award | Stock Option (Right to Buy) | 33,150 | $0.00 | - | |
| Clay B. Siegall | Grant or award | Stock Option (Right to Buy) | 33,150 | $0.00 | - | |
| Amy Kate Sasser | Grant or award | Stock Option (Right to Buy) | 33,150 | $0.00 | - | |
| Carrie Brownstein | Grant or award | Stock Option (Right to Buy) | 33,150 | $0.00 | - | |
| Michael Stewart Lee - Director | Grant or award | Stock Option (Right to Buy) | 33,150 | $0.00 | - | |
| Helen M. Boudreau | Grant or award | Stock Option (Right to Buy) | 33,150 | $0.00 | - | |
| Neil W. Gibson | Grant or award | Stock Option (Right to Buy) | 33,150 | $0.00 | - | |
| George Golumbeski | Grant or award | Stock Option (Right to Buy) | 33,150 | $0.00 | - | |
| Redmile Group, LLC - Director | Grant or award | Stock Option (Right to Buy) | 33,150 | $0.00 | - | |
| Redmile Group, LLC - Director | Open-market sale | Common Stock, par value $0.0001 per share | 133,371 | $1.25 | $167K | |
| Redmile Group, LLC - Director | Open-market purchase | Common Stock, par value $0.0001 per share | 133,371 | $1.25 | $167K | |
| Redmile Group, LLC - Director | Other | Common Stock, par value $0.0001 per share | 1,026,888 | $1.25 | $1.28M | |
| Redmile Group, LLC - Director | Other | Common Stock, par value $0.0001 per share | 1,026,888 | $1.25 | $1.28M | |
| Taylor Schreiber - Officer | Open-market purchase | Common Stock | 36,500 | $1.21 | $44K |
This is as far as the anonymous view goes. Create a free account for all 53 STTK filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Shattuck Labs, Inc. (STTK) had 14 insider filings in the last 90 days, with the most recent on 2026-07-07. The full record for STTK runs to 53 Form 4 filings, the earliest from 2024-10-08. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
5 insider purchases of STTK were filed in the last 90 days, totaling $250K.
4 insider sales of STTK were filed in the last 90 days, totaling $379K.
This page tracks STTK Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add STTK to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
